F-star is an oncology-focused biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve the standard of care for patients.
The company’s Modular Antibody Technology™ allows developers to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. It combines the power of our Fcab™ technology with traditional antibodies to identify the most appropriate target combinations, thus providing the opportunity to deliver products with the greatest therapeutic advantage to patients.
Schwarzenbergplatz 7,
A-1030 Vienna, Austria
Web: F-star
Advertisement #3 
Advertisement #4
